drugset / Trial / NCT02922348

Hormone Replacement for Premature Ovarian Insufficiency

NCT02922348

Phase 3 Withdrawn University of Pennsylvania
RandomizedParallel-groupOpen-labelTreatment

Summary

The investigators intend to establish feasibility/acceptability of a pilot randomized trial comparing hormone replacement therapy (HRT) and combined oral contraceptives (COCs) in women with premature ovarian insufficiency to estimate differences in quality of life (QOL) and serum hormone assays and markers of bone turnover/cardiovascular risk. At baseline, QOL survey will be administered and serum testing performed. Patients then randomized to HRT or COCs. Repeat testing will be performed after 3 and 6 months.

Timeline

Start
2016-03-01
Primary completion
2018-12-01
Completion
2018-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Estradiol Other / unclassified 100 ug Other
Subject Estradiol Other / unclassified 2 mg Other
Subject Norgestimate Small molecule 0.25 mg Oral
Subject Progesterone Other / unclassified 200 mg
Subject ethinyl estradiol Small molecule 0.035 mg Oral
Subject medroxyprogesterone acetate Other / unclassified 10 mg